TIMI grade flow, mortality, and the GUSTO-III trial

Pharmacotherapy

Volumn 18, Issue 4, 1998, Pages 699-705

  Stringer, Kathleen A ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; FIBRINOLYTIC AGENT; HEPARIN; RETEPLASE; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; BLEEDING; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; FIBRINOLYTIC THERAPY; HEART INFARCTION SIZE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE REPERFUSION; HEART PERFUSION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MORBIDITY; REVIEW; STROKE; TREATMENT OUTCOME;

EID: 0031826161     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. AIMS Trial Study Group. Long-term effects of intravenous anistreplase in acute myocardial infarction: final report of the AIMS study. Lancet 1990;335:427-31.
2. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397-401.
3. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected myocardial infarction: ISIS-2. Lancet 1988;2:349-60.
4. Wilcox RG, Olsson CG, Skene AM, et al. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo-Scandinavian study of early thrombolysis (ASSET). Lancet 1988;2:525-30.
5. Braunwald E. Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival. Should the paradigm be expanded? Circulation 1989;79:441-4.
6. Califf RM, Topol EJ, Gersh BJ. From myocardial salvage to patient salvage in acute myocardial infarction. The role of reperfusion therapy. J Am Coll Cardiol 1989;14:1382-8.
7. Gersh BJ, Anderson JL. Thrombolysis and myocardial salvage. Results of clinical trials and the animal paradigm-paradoxic or predictable? Circulation 1993;88:296-306.
8. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial: phase 1 findings. N Engl J Med 1985;312:932-6.
9. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992;339:753-70.
10. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico: GISSI-2. A factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990;336:65-71.
11. Bleich SD, Nichols TC, Schumacher RR, Cooke DH, Tate DA, Teichman SL. Effect of heparin on coronary artery patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 1990;66:1412-17.
12. Hsia J, Hamilton WP, Kleinman N, Roberts R, Chaitman BR, Ross AM. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1990;323:1433-7.
13. Smalling RW, Schumacher R, Morris D, et al. Improved infarct-related arterial patency after high dose, weight adjusted, rapid infusion of tissue-type plasminogen activator in myocardial infarction: results of a multicenter, randomized trial of two dosage requirements. J Am Coll Cardiol 1990;15:915-21.
14. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-82.
15. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329:1615-22.
16. Topol EJ. Which thrombolytic agent should one choose? Prog Cardiovasc Dis 1991;34:165-78.
17. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311-22.
18. Boersma E, Maas ACP, Deckers JW, Simoons ML. Early thrombolytic therapy in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996;348:771-5.
19. Newby LK, Rutsch WR, Califf RM, et al. Time from symptom onset to treatment and outcomes after thrombolytic therapy. J Am Coll Cardiol 1996;27:1646-55.
20. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO-III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997;337:1118-23.
21. Smalling RW, Bode C, Kalbfleisch J, et al. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. Circulation 1995;91:2725-32.
22. Bode C, Smalling RW, Berg G, et al. Randomized comparison of coronary thrombolysis achieved with double bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation 1996;94:891-8.
23. Ross AM, Neuhaus K-L, Ellis SG. Frequent lack of concordance among core laboratories in assessing TIMI flow grade after reperfusion therapy. Circulation 1995;92:1-718.
24. Karagounis L, Sorensen SG, Menlove RL, et al. Does thrombolysis in myocardial infarction (TIMI) perfusion grade 2 represent a mostly patent artery or a mostly occluded artery? Enzymatic and electrocardiographic evidence from the TEAM-2 study. J Am Coll Cardiol 1992;19:1-10.
25. Anderson JL, Karagounis LA, Becker LC, et al. TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction: ventriculographic, enzymatic, and electrocardiographic evidence from the TEAM-3 study. Circulation 1993;87:1829-39.
26. Vogt A, Von Essen R, Tebbe U, Feuerer W, Appel K-F, Neuhaus K-L. Impact of early perfusion status of the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction: retrospective analysis of four German multicenter studies. J Am Coll Cardiol 1993;21: 1391-5.
27. Ohman EM, Califf RM, Topol EJ, et al. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation 1990;82:781-91.
28. Cannon CP, Braunwald E. GUSTO, TIMI and the case for rapid reperfusion. Acta Cardiol 1994;49:1-8.
29. Simes RJ, Topol EJ, Holmes DR, et al. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion: importance of early and complete infarct artery reperfusion. Circulation 1995;91:1923-8.
30. Lenderink T, Simoons ML, Van Es G-A, et al. Benefit of thrombolytic therapy is sustained throughout five years and is related to TIMI perfusion grade 3 but not grade 2 flow at discharge. Circulation 1995;92:1110-16.
31. Lincoff AM, Topol EJ, Califf RM, et al. Significance of a coronary artery with thrombolysis in myocardial infarction grade 2 flow "patency" (outcome in the thrombolysis and angioplasty in myocardial infarction trials). Am J Cardiol 1995;75:871-6.
32. Coyne KS, Walker PL, Reiner JS, et al. Cardiac specific two-year mortality related to initial post-thrombolytic flow grade. J Am Coll Cardiol 1996;27:12A.
33. Stringer KA, Lindenfeld J. The GUSTO trial: is the open-artery hypothesis proven? Ann Pharmacother 1994;28:97-8.
34. Oriman EM, Topol EJ, Califf RM, et al. An analysis of the cause of early mortality after administration of thrombolytic therapy. Coron Artery Dis 1993;4:957-64.
35. Lee KL, Woodlief LH, Topol EJ, et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. Circulation 1995;91:1659-68.
36. White HD, Cross DB, Elliott JM, Noms RM, Yee TW. Long-term prognostic importance of patency of the infarct-related coronary artery after thrombolytic therapy for acute myocardial infarction. Circulation 1994;89:61-7.
37. Moss AJ, Behorin J. Prognosis and management after first myocardial infarction. N Engl J Med 1990;322:743-53.
38. Schofer J, Lins M, Mathey DG, et al. Time course of left ventricular function and coronary patency after saruplase vs streptokinase in acute myocardial infarction. Eur Heart J 1993;14:958-63.
39. Hohnloser SH, Franck P, Klingenheben T, Zabel M, Just H. Open infarct artery, late potentials, and other prognostic factors in patients after acute myocardial infarction in the thrombolytic era: a prospective trial. Circulation 1994;90:1747-56.
40. Zahger D, Karagounis LA, Cercek B, et al. Incomplete recanalization as an important determinant of thrombolysis in myocardial infarction (TIMI) grade 2 flow after thrombolytic therapy for acute myocardial infarction. Am J Cardiol 1995;76:749-52.
41. Ito H, Okamura A, Iwakura K, et al. Myocardial perfusion patterns related to thrombolysis in myocardial infarction: perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction. Circulation 1996;93:1993-9.
42. Cannon CP, McCabe CH, Diver DJ, et al. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) 4 trial. J Am Coll Cardiol 1994;24:1602-10.
43. Popovic AD, Neskovic AN, Marinkovic J, Thomas JD. Acute and long-term effects of thrombolysis after anterior wall acute myocardial infarction with serial assessment of infarct expansion and late ventricular remodeling. Am J Cardiol 1996;77:446-50.
44. Clemmensen P, Ohman EM, Sevilla DC, et al. Importance of early and complete reperfusion to achieve myocardial salvage after thrombolysis in acute myocardial infarction. Am J Cardiol 1992;70:1391-6.
45. Baigent C, Collins R. ISIS-2: 4-year mortality follow-up of 17,187 patients after fibrinolytic and anti-platelet therapy in suspected acute myocardial infarction. Circulation 1993; 88(suppl I):I-291.
46. Terrin ML, Williams DO, Kleiman NS, et al. Two-and three-year results of the Thrombolysis in Myocardial Infarction (TIMI) phase II clinical trial. J Am Coll Cardiol 1993;22: 1763-72.
47. International Joint Efficacy Comparison of Thrombolytics. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. Lancet 1995;346:329-36.